Altiratinib

DB17191InvestigationalSmall molecule

Altiratinib: Overview.

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor, Angiopoietin-1 receptor, and Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₂₆H₂₁F₃N₄O₄ · 510.473 g/mol (avg)
Also known as: 1,1-cyclopropanedicarboxamide, n-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)- · N-(4-((2-((cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-n-(4- fluorophenyl)cyclopropane-1,1-dicarboxamide
Code names: DCC-2701 · DP-5164

Resolves to

Compound

Structure

InChIKeyGNNDEPIMDAZHRQ-UHFFFAOYSA-NSMILESFC1=CC=C(NC(=O)C2(CC2)C(=O)NC2=C(F)C=C(OC3=CC=NC(NC(=O)C4CC4)=C3)C(F)=C2)C=C1

Targets

What you can answer from here — as of June 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

21+ReferencesStructured and connected to the statements they support

Which drugs share a target with Altiratinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.